- Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez, P., Wyrwicz, L. S., Shen, L., Ostapenko, Y., Bilici, M., Chung, H. C., Shitara, K., Qin, S.-K., Van Cutsem, E., Tabernero, J., Li, K., Shih, C.-S., Bhagia, P., … KEYNOTE-811, I. (2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/S0140-6736(23)02033-0
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
on 15 de gener de 2024
with No hi ha comentaris
Deixa un comentari